Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

(2009) S-W Han et al.   BRITISH JOURNAL OF CANCER

Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells

(2008) C. M. Sloss et al.   CLINICAL CANCER RESEARCH

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines

(2008) Jens Wagenblast et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells

(2008) Tina Cascone et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells

(2008) Changyou Li et al.   MOLECULAR CANCER THERAPEUTICS

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE